Aveanna Healthcare (NASDAQ:AVAH) CFO Matthew Buckhalter Sells 9,351 Shares of Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) CFO Matthew Buckhalter sold 9,351 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $7.65, for a total value of $71,535.15. Following the completion of the transaction, the chief financial officer owned 555,922 shares of the company’s stock, valued at $4,252,803.30. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Matthew Buckhalter also recently made the following trade(s):

• On Thursday, February 19th, Matthew Buckhalter sold 13,512 shares of Aveanna Healthcare stock. The shares were sold at an average price of $7.21, for a total value of $97,421.52.
• On Wednesday, February 18th, Matthew Buckhalter sold 13,167 shares of Aveanna Healthcare stock. The stock was sold at an average price of $7.38, for a total value of $97,172.46.
• On Friday, January 2nd, Matthew Buckhalter sold 18,340 shares of Aveanna Healthcare stock. The shares were sold at an average price of $7.85, for a total value of $143,969.00.
• On Wednesday, December 31st, Matthew Buckhalter sold 17,289 shares of Aveanna Healthcare stock. The shares were sold at an average price of $8.18, for a total transaction of $141,424.02.
• On Tuesday, December 30th, Matthew Buckhalter sold 17,448 shares of Aveanna Healthcare stock. The stock was sold at an average price of $8.36, for a total transaction of $145,865.28.

Aveanna Healthcare Trading Down 1.8%

AVAH stock traded down $0.13 on Friday, hitting $7.29. 224,424 shares of the company were exchanged, compared to its average volume of 1,230,737. The company has a debt-to-equity ratio of 140.39, a current ratio of 1.23 and a quick ratio of 1.23. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of 20.26 and a beta of 2.06. Aveanna Healthcare Holdings Inc. has a twelve month low of $3.67 and a twelve month high of $10.32. The business’s fifty day moving average is $8.48 and its two-hundred day moving average is $8.44.

More Aveanna Healthcare News

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Insiders still retain meaningful stakes — despite the sales, CEO Jeff Shaner, CFO Matthew Buckhalter and other insiders continue to hold multi‑million‑dollar positions, which may signal ongoing alignment with shareholders. SEC Filing
• Neutral Sentiment: Reported short interest data shows zero shares (likely a data/reporting anomaly), so there’s no clear short‑selling pressure indicated by that statistic. Short Interest
• Neutral Sentiment: Today’s trading volume was well below the recent average, which can amplify price moves when large block trades or news hit the tape. (Context from recent price/volume data.)
• Negative Sentiment: Large, concentrated insider selling across Feb. 17–19: CEO Jeff Shaner sold roughly 461,900 shares across the three days (totaling about $3.4M), other executives including an additional director and senior officers sold substantial blocks, and cumulative insider disposals during the period totalled in the high hundreds of thousands of shares — a clear negative catalyst that likely pushed the stock down. See CEO filings. CEO Sales SEC Filing
• Negative Sentiment: Multiple additional executive/director sales (CFO, CAO, and other insiders sold across the same dates), including material dispositions by Edwin C. Reisz and Patrick A. Cunningham, reinforcing a market interpretation that insiders are taking profits or reducing exposure at current levels. Example filings here. Other Insider Filings
• Negative Sentiment: Coverage/analysis noting the drop: independent commentary flagged the same insider selling as the primary reason for a recent ~5.7% pullback, reinforcing market attention on the sales. AAII Article

Institutional Investors Weigh In On Aveanna Healthcare

A number of hedge funds have recently bought and sold shares of AVAH. AustralianSuper Pty Ltd acquired a new stake in shares of Aveanna Healthcare during the third quarter worth approximately $15,743,000. Vanguard Group Inc. grew its holdings in Aveanna Healthcare by 38.0% during the 4th quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock worth $45,564,000 after acquiring an additional 1,535,351 shares in the last quarter. Millennium Management LLC increased its position in shares of Aveanna Healthcare by 1,007.1% in the 4th quarter. Millennium Management LLC now owns 1,114,717 shares of the company’s stock worth $9,107,000 after purchasing an additional 1,014,030 shares during the last quarter. Nuveen LLC raised its stake in shares of Aveanna Healthcare by 135.9% in the 4th quarter. Nuveen LLC now owns 1,571,308 shares of the company’s stock valued at $12,838,000 after purchasing an additional 905,316 shares in the last quarter. Finally, Hillsdale Investment Management Inc. bought a new position in shares of Aveanna Healthcare during the third quarter worth about $7,922,000. Institutional investors and hedge funds own 87.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Monday, December 29th. Jefferies Financial Group increased their target price on shares of Aveanna Healthcare from $11.00 to $12.50 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. UBS Group lifted their price target on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the company a “neutral” rating in a research report on Thursday, January 15th. William Blair began coverage on Aveanna Healthcare in a research report on Monday, December 8th. They issued an “outperform” rating for the company. Finally, Truist Financial boosted their price target on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a research report on Friday, November 7th. Five analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $11.06.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.